{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:09:07Z","timestamp":1767848947584,"version":"3.49.0"},"reference-count":37,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,12,1]]},"abstract":"<jats:p>Propranolol treatment was recently reported to be successful for the management of severe infantile hemangioma. Known adverse effects of propranolol treatment include transient bradycardia, hypotension, hypoglycemia, and bronchospasm (in patients with underlying spastic respiratory illnesses), which led to a general recommendation to gradually increase propranolol dosage and closely monitor patients' hemodynamics at the onset of therapy. To date, no serious or unexpected adverse effects that required specific intervention have been reported. In this report, we describe the case of a 17-week-old female preterm infant who presented with a large, ulcerated, cutaneous-subcutaneous hemangioma of the right lateral thoracic wall, which we treated successfully with propranolol. A few days into therapy, a potentially life-threatening adverse effect, severe hyperkalemia, was observed and required treatment with loop diuretics, fluids, and nebulized salbutamol to normalize her serum potassium levels. This therapy could be gradually tapered and finally discontinued only after several weeks of propranolol treatment. Our case report indicates that, at least during the initial phase of the propranolol treatment of infantile hemangioma, close monitoring of serum electrolytes, besides the monitoring of hemodynamics and blood glucose, is necessary.<\/jats:p>","DOI":"10.1542\/peds.2010-0077","type":"journal-article","created":{"date-parts":[[2010,11,30]],"date-time":"2010-11-30T05:12:07Z","timestamp":1291093927000},"page":"e1589-e1593","source":"Crossref","is-referenced-by-count":78,"title":["Hyperkalemia Complicating Propranolol Treatment of an Infantile Hemangioma"],"prefix":"10.1542","volume":"126","author":[{"given":"Helena","family":"Pavlakovi\u0107","sequence":"first","affiliation":[{"name":"Departments of Pediatrics I,"},{"name":"Anatomy and Cell Biology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Kietz","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics I,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Lauerer","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics I,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Zutt","sequence":"additional","affiliation":[{"name":"Dermatology, University Hospital G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Lakomek","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics I,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2010,12,1]]},"reference":[{"issue":"3","key":"2021121007004820000_B1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1056\/NEJM199907153410307","article-title":"Hemangiomas in children","volume":"341","author":"Drolet","year":"1999","journal-title":"N Engl J Med"},{"issue":"24","key":"2021121007004820000_B2","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1056\/NEJMc0708819","article-title":"Propranolol for severe hemangiomas of infancy","volume":"358","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","journal-title":"N Engl J Med"},{"issue":"10","key":"2021121007004820000_B3","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/lary.20633","article-title":"Propranolol for airway hemangiomas: case report of novel treatment","volume":"119","author":"Buckmiller","year":"2009","journal-title":"Laryngoscope"},{"issue":"3","key":"2021121007004820000_B4","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2008-3458","article-title":"Propranolol for severe infantile hemangiomas: follow-up report","volume":"124","author":"Sans","year":"2009","journal-title":"Pediatrics"},{"issue":"2","key":"2021121007004820000_B5","first-page":"133","article-title":"Hemangioma: classification and recommendations for therapy. [in German]","volume":"10","author":"Cremer","year":"2009","journal-title":"P\u00e4diatrie Hautnah"},{"issue":"26","key":"2021121007004820000_B6","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1056\/NEJMc086443","article-title":"More on propranolol for hemangiomas of infancy","volume":"359","author":"Siegfried","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"2021121007004820000_B7","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1442-9071.2010.02327.x","article-title":"Successful treatment of infantile haemangiomas of the orbit with propranolol","volume":"38","author":"Li","year":"2010","journal-title":"Clin Experiment Ophthalmol"},{"issue":"3","key":"2021121007004820000_B8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000291300","article-title":"Propranolol as a novel treatment for congenital visceral haemangioma","volume":"98","author":"Vanlander","year":"2010","journal-title":"Neonatology"},{"issue":"2","key":"2021121007004820000_B9","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/archophthalmol.2009.375","article-title":"Propranolol for isolated orbital infantile hemangioma","volume":"128","author":"Fay","year":"2010","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"2021121007004820000_B10","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1468-3083.2010.03603.x","article-title":"Successful treatment of ulcerated haemangioma with propranolol","volume":"24","author":"Naouri","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2021121007004820000_B11","doi-asserted-by":"crossref","first-page":"195.e1","DOI":"10.1016\/j.ophtha.2009.08.040","article-title":"Propranolol for orbital hemangioma","volume":"117","author":"Taban","year":"2010","journal-title":"Ophthalmology"},{"issue":"2","key":"2021121007004820000_B12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jpeds.2009.10.010","article-title":"Propranolol for the treatment of a life-threatening subglottic and mediastinal infantile hemangioma","volume":"156","author":"Truong","year":"2010","journal-title":"J Pediatr"},{"issue":"5","key":"2021121007004820000_B13","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1525-1470.2009.00975.x","article-title":"Propranolol treatment for hemangioma of infancy: risks and recommendations","volume":"26","author":"Lawley","year":"2009","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"2021121007004820000_B14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2133.2009.09597.x","article-title":"Propranolol for complicated infantile haemangiomas: a case series of 30 infants","volume":"162","author":"Manunza","year":"2010","journal-title":"Br J Dermatol"},{"issue":"1","key":"2021121007004820000_B15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/pbc.22262","article-title":"Massive response of severe infantile hepatic hemangioma to propanolol","volume":"54","author":"Marsciani","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2021121007004820000_B16","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/lary.20807","article-title":"Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center","volume":"120","author":"Buckmiller","year":"2010","journal-title":"Laryngoscope"},{"key":"2021121007004820000_B17","first-page":"e17","article-title":"Enzymatic debriding agents are safe in wounds with high bacterial bioburdens and stimulate healing","volume":"8","author":"Payne","year":"2008","journal-title":"Eplasty"},{"issue":"5","key":"2021121007004820000_B18","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1525-1470.2005.00119.x","article-title":"Debridement via collagenase application in two neonates","volume":"22","author":"Tiras","year":"2005","journal-title":"Pediatr Dermatol"},{"issue":"9","key":"2021121007004820000_B19","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/archderm.137.9.1208","article-title":"Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation","volume":"137","author":"Bennett","year":"2001","journal-title":"Arch Dermatol"},{"issue":"4","key":"2021121007004820000_B20","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1610-0387.2008.06657.x","article-title":"Hemangiomas in infancy and childhood. Guideline of the German Society of Dermatology with the working group Pediatric Dermatology together with the German Society for Pediatric Surgery and the German Society for Pediatric Medicine","volume":"6","author":"Grantzow","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"2021121007004820000_B21","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1097\/00006534-199911000-00002","article-title":"Complications of systemic corticosteroid therapy for problematic hemangioma","volume":"104","author":"Boon","year":"1999","journal-title":"Plast Reconstr Surg"},{"issue":"8","key":"2021121007004820000_B22","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/archderm.140.8.963","article-title":"Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas","volume":"140","author":"George","year":"2004","journal-title":"Arch Dermatol"},{"issue":"5","key":"2021121007004820000_B23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1525-1470.2005.00102.x","article-title":"Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7\u20139, 2005, Bethesda, Maryland, USA","volume":"22","author":"Frieden","year":"2005","journal-title":"Pediatr Dermatol"},{"key":"2021121007004820000_B24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/B978-0-323-02367-2.50020-1","article-title":"Pharmacologic treatment of heart disease","volume-title":"Pediatric Cardiology: The Requisites in Pediatrics","author":"Tanel","year":"2006"},{"key":"2021121007004820000_B25","first-page":"296","article-title":"Disorders of cardiac rhythm and conduction","volume-title":"Moss and Adams' Heart Disease in Infants, Children and Adolescents","author":"Kannankeril","year":"2008","edition":"7th ed."},{"issue":"8","key":"2021121007004820000_B26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJM198002213020803","article-title":"Adrenergic modulation of extrarenal potassium disposal","volume":"302","author":"Rosa","year":"1980","journal-title":"N Engl J Med"},{"issue":"1","key":"2021121007004820000_B27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF00280106","article-title":"Comparison of the effects of xamoterol, atenolol and propranolol on breathlessness, fatigue and plasma electrolytes during exercise in healthy volunteers","volume":"41","author":"S\u00f8rensen","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"2021121007004820000_B28","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1097\/00005344-199006165-00009","article-title":"Beta-receptor blockade, physical activity, and metabolism","volume":"16","author":"Lohmann","year":"1990","journal-title":"J Cardiovasc Pharmacol"},{"key":"2021121007004820000_B29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.0954-6820.1983.tb01624.x","article-title":"The effect of adrenergic blockade on potassium concentrations in different conditions","volume":"672","author":"Lundborg","year":"1983","journal-title":"Acta Med Scand Suppl"},{"key":"2021121007004820000_B30","volume-title":"British National Formulary 48","author":"British Medical Association Staff","year":"2004","edition":"48th ed."},{"issue":"2","key":"2021121007004820000_B31","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2133.2010.09848.x","article-title":"Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action","volume":"163","author":"Storch","year":"2010","journal-title":"Br J Dermatol"},{"issue":"5","key":"2021121007004820000_B32","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1290\/1071-2690(2002)038<0298:BBIAIC>2.0.CO;2","article-title":"Beta blockade induces apoptosis in cultured capillary endothelial cells","volume":"38","author":"Sommers Smith","year":"2002","journal-title":"In Vitro Cell Dev Biol Anim"},{"issue":"8","key":"2021121007004820000_B33","first-page":"1117","article-title":"Cell kinetics and chemotherapy: a critical review","volume":"62","author":"Tannock","year":"1978","journal-title":"Cancer Treat Rep"},{"issue":"7","key":"2021121007004820000_B34","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.jp.7200197","article-title":"Progressive tumor necrosis and lethal hyperkalemia in a neonate with sacrococcygeal teratoma (SCT)","volume":"19","author":"Jona","year":"1999","journal-title":"J Perinatol"},{"issue":"1","key":"2021121007004820000_B35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br J Haematol"},{"key":"2021121007004820000_B36","first-page":"61","article-title":"Incidence and pathogenesis of tumor lysis syndrome","volume":"147","author":"Locatelli","year":"2005","journal-title":"Contrib Nephrol"},{"issue":"16","key":"2021121007004820000_B37","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review","volume":"26","author":"Coiffier","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/126\/6\/e1589\/1054829\/zpe012100e1589.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/126\/6\/e1589\/1054829\/zpe012100e1589.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T16:06:16Z","timestamp":1711987576000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/126\/6\/e1589\/65009\/Hyperkalemia-Complicating-Propranolol-Treatment-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,1]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2010,12,1]]},"published-print":{"date-parts":[[2010,12,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2010-0077","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,1]]}}}